Article
Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Diagnostic pathology - 9 Feb 2016
Bae Ja Seong, Kim Yourha, Jeon Sora, Kim Se Hee, Kim Tae Jung, Lee Sohee, Kim Min-Hee, Lim Dong Jun, Lee Youn Soo, Jung Chan Kwon
Abstract excerpt
BACKGROUND: Mutations in the TERT promoter, ALK rearrangement, and the BRAF V600E mutation are associated with aggressive clinicopathologic features in thyroid cancers. However, little is known about the impact of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of BRAF mutations. METHODS: We performed Sanger sequencing to detect BRAF V600E and TERT promoter...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.